FDA to revisit GMP for raw materials

The US Food and Drug Administration says it plans to revise good manufacturing practice (GMP) regulations for incoming raw materials to help industry secure the pharmaceutical supply chain against economically-motivated adulteration, according to a report on FDAnews.com (subscription required).

The agency says it has not committed to any particular timeline for the revisions, but it expects they will significantly improve the control over suppliers, says the report.

The piece refers to comments made by Deb Autor, director of the Office of Compliance at the FDA's Center for Drug Evaluation and Research, at the 2010 PDA/FDA Pharmaceutical Supply Chain Workshop in Bethesda, Maryland, earlier this week.